OTLC Insider Trading Activity and SEC Form 4 Filings
OTLC insider trading summary
Over the past 12 months, insiders at Oncotelic Therapeutics, Inc. (OTLC) reported 8 open-market purchases worth $51K by 2 insiders and no sales on SEC Form 4. Net insider buying was $51K.
Latest OTLC insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 29, 2026 | Vuong Trieu | Chairman and CEO | Buy | $18K (1,044,990 @ $0.02) |
| Oct 28, 2026 | Vuong Trieu | Chairman and CEO | Buy | $6K (312,000 @ $0.02) |
| Jun 24, 2026 | Vuong Trieu | Chairman and CEO | Buy | $5K (115,000 @ $0.04) |
| Jun 23, 2026 | Vuong Trieu | Chairman and CEO | Buy | $3K (75,000 @ $0.04) |
| Jun 22, 2026 | Vuong Trieu | Chairman and CEO | Buy | $3K (65,000 @ $0.04) |
| Jun 22, 2026 | Amit B. Shah | CFO | Buy | $1K (20,000 @ $0.05) |
| Jun 17, 2026 | Vuong Trieu | Chairman and CEO | Buy | $11K (239,759 @ $0.04) |
| Jun 15, 2026 | Vuong Trieu | Chairman and CEO | Buy | $4K (96,000 @ $0.04) |
| Jul 10, 2025 | Vuong Trieu | Chairman and CEO | Buy | $520 (104,000 @ $0.01) |
| Jul 9, 2025 | Vuong Trieu | Chairman and CEO | Buy | $0 (1 @ $0.01) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.